Pffffttttttt! you wish buddy. MSB is luck to be worth $2 in its current state and it won't be long you will be holding under $2. Ofcourse you will still say there is promise. There is no point even having a discussion because you will just hang onto any tiny hope just like a sunk submarine. If you were competent you would admit since December 2020 Mesoblast all 4 trials have been a disaster. Novartis deal still in the air clearly they aren't jumping all over it and taking there time. Either the data isn't that good or Mesoblast is a low priority for them.
This leaves Mesoblast with 4 drugs with some promise but all needing very expensive stage 3 trials and in the case of CHF and CLBP will take not only hundreds of millions but also 3 years to complete the trial. To market say another 18 months. That's the situation unless you get a partner but even then they would just fund the trial it won't guarantee any success. To get all 4 trials going again it will require a huge investment. My opinion is pick 2 and just focus on them. This scatter approach shows how management cannot control the trials and are overwhelmed. They need to ensure patients meet specific criteria before being allowed to enter the trial. This was a critical mistake in most of the trials including ARDS, CLBP. But to not acknowledge the mistakes of management and simply say they're doing great means nothing. The scoreboard is the share price and at 2011 the SP was over $10 10 years later your still below $2.50 with no dividends nothing. Just more dilution every single year by isuuing options and empty promises.
MSB Price at posting:
$2.46 Sentiment: Sell Disclosure: Not Held
(20min delay)